Table 2 PET tracer detection rates
From: A dual-tracer approach using [11C]CH and [18F]FDG in HCC clinical decision making
18F-FDG | 11C-CH | ||
|---|---|---|---|
Detection rate Critical findingb | 13/19 (68%) | 16/19 (84%) | |
Detection rate non-critical finding | 5/8 (63%) | 4/8 (50%) | |
Differentiationa | Well | 3/4 (75%) | 4/4 (100%) |
Moderately | 1/2 (50%) | 2/2 (100%) | |
Poorly | 3/3 100% | 3/3 (100%) | |
Multifocal HCC | Recurrence | 10/16 (63%) | 11/16 (69%) |
Vascular involvement | 1/1 (100%) | 0/1 (0%) | |
Total | 11/17 (65%) | 11/17 (65%) | |
Extrahepatic HCC | Soft tissue | 2/4 (50%) | 2/4 (50%) |
Bone | 1/1 (100%) | 1/1 (100%) | |
Lymph node | 6/8 (75%) | 6/8 (75%) | |
Total | 11/13 (80%) | 9/13 (73%) | |
New primary tumours | 1/2 (50%) | 2/2 (100%) | |
Therapy-related | Needle tract metastases | 0/2 (0%) | 2/2 (100%) |
Ablation site recurrence | 4/5 (80%) | 2/5 (40%) | |
Total | 4/7 (57%) | 4/7 (57%) |